Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.01
At close: Mar 31, 7:21 AM EDT
$8.04
0.030.37%
After Hours: 7:21 AM EDT
Comments
Loading...
Avalo Therapeutics Analyst Ratings and Price Targets | NASDAQ:AVTX | Benzinga
Avalo Therapeutics Inc has a consensus price target of $26.22 based on the ratings of 9 analysts. The high is $48 issued by Piper Sandler on February 28, 2025. The low is $0.75 issued by RBC Capital on June 27, 2023. The 3 most-recent analyst ratings were released by Jefferies, Stifel, and Piper Sandler on March 25, 2025, March 25, 2025, and February 28, 2025, respectively. With an average price target of $35.67 between Jefferies, Stifel, and Piper Sandler, there's an implied 343.62% upside for Avalo Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Stifel
Piper Sandler
BTIG
LUCID CAPITAL MARKETS
1calculated from analyst ratings
Analyst Ratings for Avalo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 186.07% | Jefferies | Kambiz Yazdi63% | → $23 | Initiates | → Buy | Get Alert |
| 03/25/2025 | Buy Now | 347.76% | Stifel | Alex Thompson69% | → $36 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | — | HC Wainwright & Co. | Edward White46% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/28/2025 | Buy Now | 497.01% | Piper Sandler | Yasmeen Rahimi27% | → $48 | Initiates | → Overweight | Get Alert |
| 12/19/2024 | Buy Now | 397.51% | BTIG | Julian Harrison44% | → $40 | Initiates | → Buy | Get Alert |
| 12/17/2024 | Buy Now | 198.51% | LUCID CAPITAL MARKETS | Dev Prasad 42% | → $24 | Initiates | → Buy | Get Alert |
| 10/24/2024 | Buy Now | — | HC Wainwright & Co. | Edward White46% | — | Initiates | → Neutral | Get Alert |
| 04/16/2024 | Buy Now | 335.32% | Oppenheimer | Leland Gershell70% | → $35 | Upgrade | Perform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | — | Oppenheimer | Leland Gershell70% | — | Downgrade | Outperform → Perform | Get Alert |
| 06/27/2023 | Buy Now | -90.67% | RBC Capital | Gregory Renza47% | $2160 → $180 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | Buy Now | 11.94% | RBC Capital | Gregory Renza47% | $4080 → $2160 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | -62.69% | Jefferies | Chris Howerton64% | → $720 | Downgrade | Hold → Underperform | Get Alert |
FAQ
What is the target price for Avalo Therapeutics (AVTX) stock?
The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Jefferies on March 25, 2025. The analyst firm set a price target for $23.00 expecting AVTX to rise to within 12 months (a possible 186.07% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avalo Therapeutics (AVTX)?
The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Jefferies, and Avalo Therapeutics initiated their buy rating.
When was the last upgrade for Avalo Therapeutics (AVTX)?
The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.
When was the last downgrade for Avalo Therapeutics (AVTX)?
The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Avalo Therapeutics (AVTX) correct?
While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $23.00. The current price Avalo Therapeutics (AVTX) is trading at is $8.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.